Reduced expression of PER3 is associated with incidence and development of colon cancer

Annals of Surgical Oncology

Volumn 19, Issue 9, 2012, Pages 3081-3088

  Wang, Xiaoliang ^a   Yan, Dongwang ^a   Teng, Mujian ^b   Fan, Junwei ^a   Zhou, Chongzhi ^a   Li, Dawei ^a   Qiu, Guoqiang ^a   Sun, Xing ^a   Li, Tao ^a   Xing, Tonghai ^a   Tang, Huamei ^a   Peng, Xiao ^c   Peng, Zhihai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c The First People s Hospital of Changde City)   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PERIOD PROTEIN 3; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER STAGING; CANCER TISSUE; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RECTUM CANCER; TUMOR DIFFERENTIATION;

AGED; CARCINOMA; COLON; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERIOD CIRCADIAN PROTEINS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

EID: 84867401721     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2279-5     Document Type: Article

References (25)

1. Nelson RS, Thorson AG. Colorectal cancer screening. Curr Oncol Rep. 2009;11:482-9.
2. Labianca R, Beretta GD, Kildani B, et al. Colon cancer. Crit Rev Oncol Hematol. 2010;74:106-33.
3. Li M, Gu J. Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol. 2005;11:4685-8.
4. Fan J, Peng Z, Zhou C, et al. Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genomewide gene-expression analyses: identification and validation of IFITM3 as a biomarker of early colon carcinogenesis. Cancer. 2008;113:266-75.
5. Eriguchi M, Levi F, Hisa T, Yanagie H, Nonaka Y, Takeda Y. Chronotherapy for cancer. Biomed Pharmacother. 2003;57:92s-5s.
6. Archer SN, Robilliard DL, Skene DJ, et al. A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep. 2003;26:413-5.
7. Ebisawa T, Uchiyama M, Kajimura N, et al. Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome. EMBO Rep. 2001;2:342-6.
8. Johansson C, Willeit M, Smedh C, et al. Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology. 2003;28:734-9.
9. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005;26:1241-6.
10. Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev. 2005;14:268-70.
11. Lin YM, Chang JH, Yeh KT, et al. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog. 2008;47:925-33.
12. Tokunaga H, Takebayashi Y, Utsunomiya H, et al. Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2008;87:1060-70.
13. Zhu Y, Stevens RG, Hoffman AE, et al. Testing the circadian gene hypothesis in prostate cancer: a population-based casecontrol study. Cancer Res. 2009;69:9315-22.
14. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003;3:350-61.
15. Yang MY, Chang JG, Lin PM, et al. Down-regulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci. 2006;97:1298-307.
16. Engstrom PF, Benson AB 3rd, Chen YJ, et al. Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005;3:468-91.
17. Li D, Yan D, Tang H, et al. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 2009;16:3499-506.
18. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418:935-41.
19. Barnes JW, Tischkau SA, Barnes JA, et al. Requirement of mammalian Timeless for circadian rhythmicity. Science. 2003;302:439-42.
20. Garceau NY, Liu Y, Loros JJ, Dunlap JC. Alternative initiation of translation and time-specific phosphorylation yield multiple forms of the essential clock protein frequency. Cell. 1997;89:469-76.
21. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003;302:255-9.
22. Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 2009;9:886-96.
23. Shih HC, Choo KB, Chang TJ, et al. Disturbance of circadian gene expression in endometrial cancer: detection by real-time quantitative RT-PCR. Oncol Rep. 2005;14:1533-8.
24. Im JS, Jung BH, Kim SE, Lee KH, Lee JK. Per3, a circadian gene, is required for Chk2 activation in human cells. FEBS Lett. 2010;584:4731-4.
25. Keith LG, Oleszczuk JJ, Laguens M. Circadian rhythm chaos: a new breast cancer marker. Int J Fertil Womens Med. 2001;46:238-47.